StreetAlpha.app
Home › Stocks › UPB

Upstream Bio, Inc. (UPB)

Healthcare
$1.59
▼ −20.50%
LAST CLOSE · NOV 20

Upstream Bio develops verekitug, an experimental antibody drug for severe asthma, nasal polyps and COPD. It last closed at $1.59 on Nov 20, down 20.50% on the day. The next earnings report for UPB is expected around Wed, Feb 10, 2027. For the quarter ended Sep 2026, UPB reported EPS of -$0.75 on revenue of $395,000, with revenue down 42.2% from a year ago. Over its last 8 reports the stock moved an average of 10.4% the session after earnings. Over the last 12 months UPB insiders bought $0 of stock on the open market and sold $105K, according to SEC Form 4 filings.

AI Auto Pilots
Is UPB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold UPB.

Key Stats

Last 12 months
Results
Revenue
$2.9M
+2.5% vs a year ago
Net income
−$163.9M
−5712.3% margin
EPS (diluted)
−$3.01
−128.2% vs a year ago
Free cash flow
−$168.4M
−5867.2% margin
Valuation
Market cap
$87.2M
54.8M shares
P/E
–
No P/E while losing money
Price to sales
30.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$47.4M
At Sep 30
Shareholder equity
$234.0M
Shares outstanding
54.8M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $2.4M$2.4MFY2023FY2024: $2.4M$2.4MFY2024FY2025: $2.9M$2.9MFY2025

From UPB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 10
Estimated date · Time not announced
Reported EPS
-$0.75
Quarter ended Sep 2026
Year ago EPS
-$0.63
Same quarter last year
Revenue
$395,000
−42.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $12.57Dec '24Mar 2025: -$0.51Mar '25Jun 2025: -$0.74Jun '25Sep 2025: -$0.63Sep '25Dec 2025: -$0.78Dec '25Mar 2026: -$0.75Mar '26Jun 2026: -$0.73Jun '26Sep 2026: -$0.75Sep '26Latest -$0.75
Revenue by quarter
Dec 2024: $613,000Dec '24Mar 2025: $566,000Mar '25Jun 2025: $937,000Jun '25Sep 2025: $683,000Sep '25Dec 2025: $668,000Dec '25Mar 2026: $1.0MMar '26Jun 2026: $773,000Jun '26Sep 2026: $395,000Sep '26Latest $395,000
How UPB moved after its last 8 reports
Average move the session after a report ±10.4%
Nov 10, 2026Time not announced−5.6%
Aug 11, 2026Time not announced−4.7%
May 13, 2026Time not announced+4.6%
Mar 26, 2026Time not announced+3.4%
Feb 11, 2026Time not announced−47.2%
Nov 5, 2025Time not announced−4.3%
Aug 6, 2025Time not announced+7.9%
May 6, 2025Time not announced−5.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on UPBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on UPB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on UPB

Technical Analysis

UPB · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 82% below its 20 day and 142% below its 50 day average. It is 353% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $1.56, and the nearest resistance the Pivot at $1.74.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 21.9%/day
Key levels
$33.6852 week high+2018.2%
$7.20200 day average+352.8%
$5.34100 day average+235.8%
$3.8450 day average+141.5%
$3.84Swing high (Nov 4)+141.5%
$2.8920 day average+81.8%
$1.91Pivot R1+20.1%
$1.74Pivot+9.4%
$1.59Last close
$1.5652 week low−1.9%
$1.41Pivot S1−11.3%
Indicators
RSI (14)22.77Oversold below 30Oversold
MACD-0.52Below its signal lineBearish
Stochastic1.8Near the bottom of its rangeOversold
ADX (14)39.0Trending down
Williams %R-98.7Oversold below −80, overbought above −20Oversold
CCI (20)-174.7Oversold below −100, overbought above 100Oversold
Rate of change−50.8%Change over 10 sessionsBearish
ATR (14)$0.35Typical daily range, 21.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for UPB

What happened before

See how UPB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for UPBHow many large options trades hit UPB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

UPB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●74 buying vs 78 selling
  • ▼Held by funds -4.4 pts
  • ▼Funds holding -14
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding135149−9.4%
In funds' top 10220.0%
Held by funds87.9%92.3%−4.4 pts
New / increased18 / 5637 / 65−27.5%
Reduced / sold out47 / 3128 / 28+39.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See UPB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

UPB Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$105K15 sales · 5 insiders
2026-03 sold $47K2026-06 sold $31K2026-09 sold $28KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 16Allison AmbroseGeneral CounselSale485$5.49$3K
Sep 16Michael GrayCFO and COOSale853$5.49$5K
Sep 16Adam HoughtonChief Business OfficerSale700$5.49$4K
Sep 16Everett Rand SutherlandCEOSale2,095$5.49$12K
Sep 16Aaron DeykinChief Medical OfficerSale895$5.49$5K
Jun 16Allison AmbroseGeneral CounselSale477$6.10$3K
Every insider buy and sale for UPB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See UPB insider trades →

From SEC Form 4 filings by UPB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UPB is in one of them and how their past UPB trades turned out.

UPB in the AI portfolios
Loading…

UPB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered UPB in an article yet. Here's the latest on the wider market.

UPB in the news

About Upstream Bio

Upstream Bio is a biotechnology company based in Waltham, Massachusetts, that develops treatments for inflammatory diseases. Its main candidate, verekitug, is a monoclonal antibody that blocks the receptor for a protein called TSLP, which plays a role in immune responses. The company is testing verekitug in clinical trials for severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease. The drug is not yet approved, and its intended patients are people with these lung and airway conditions.

Headquarters
Waltham, MA